The Company’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” will take place on March 7 at 1:30pm EST
RANCHO CORDOVA, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of ThermoGenesis Corp., Cesca’s device division, will be presenting at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech). ISBiotech is being held March 5-7, 2018 at the Hilton Norfolk The Main Hotel in Norfolk, Virginia.
Mr. Coelho’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” is scheduled to take place on Wednesday, March 7 from 1:30-2:15pm EST.
For more information about the ISBiotech Spring Meeting, go to: www.isbiotech.org
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Cesca Therapeutics Inc.
Source: Cesca Therapeutics Inc.